RESUMO
Objective To construct a fluorescent expression cell model of botulinum toxin type B light chain(BoNT/B,BLC),and evaluate the effect of small molecule compounds with this model.Methods The BLC gene was inserted into the fluorescent expression vector pEGFP-N1 to construct a recombinant plasmid before being transfected into the neural cell line Neuro-2a cells for expression.The fluorescence expression level of BLC-EGFP protein in the cells was observed under a fluorescence microscope,and the enzyme digestion activity and stability of BLC-EGFP in the cells were detected by Western blotting.Furthermore,the model was used to evaluate the effect of SRC kinase inhibitor KX2-391 on the intracellular stability of BLC-EGFP protein.Results The recombinant expression plasmid pEGFP-N1-BLC was constructed.It was found that the expression level of BCL-EGFP protein in Neuro-2a cells gradually increased over time,and that the intracellular substrate vesicle-associated membrane protein-2(VAMP-2)was cleaved after plasmid transfection.CHX was added to terminate protein synthesis after the plasmid was transfected for 12 h,and the intracellular level of BLC-EGFP did not change significantly within 72 h.Twenty-four hours of treatment with KX2-391 could significantly promote the intracellular degradation of BLC-EGFP protein.Conclusions A cell model of fluorescent expression of botulinum toxin type B light chain has been established,which provides a technical reserve for the subsequent study onthe intracellular persistence mechanism and intracellular antidote screening of botulinum toxin type B light chain.
RESUMO
PURPOSE: To report a case of temporary accommodation difficulties after botulinum toxin injections for the treatment of palmar and plantar hyperhidrosis. CASE SUMMARY: A 27-year-old woman presented with difficulties performing near work that had begun 1 week prior. She underwent injections of botulinum toxin type B (Myobloc(R)) for the treatment of both palmar and plantar hyperhidrosis 3 weeks earlier. The patient had subdermal injections of 3000 MU (mouse unit) of Myobloc(R) on each palm and sole. On manifest refraction, the patient was emmetropic. Near point of accommodation was 32 cm in the right eye and 25 cm in the left eye, near point of convergence was 10 cm, and the monocular accommodative power measured with minus lenses was 1.5 diopter (D) in the right eye and 2.0 D in the left eye. After 3 weeks, accommodation difficulties were completely resolved and hyperhidrosis symptoms did not recur. CONCLUSIONS: Ophthalmologic adverse effects related to the autonomic nervous system such as accommodation difficulties may occur with injections of botulinum toxin type B for the treatment of hyperhidrosis. These symptoms should be explained carefully to the patient before the botulinum toxin injection procedure.
Assuntos
Feminino , Humanos , Sistema Nervoso Autônomo , Toxinas Botulínicas , Olho , HiperidroseRESUMO
Obturator nerve block has been commonly used for pain management to prevent involuntary reflex of the adductor thigh muscles. One of several options for this block is chemical neurolysis. Neurolysis is done with chemical agents. Chemical agents used in the neurolysis of the obturator nerve have been alcohol, phenol, and botulinum toxin. In the current case, a patient with spasticity of the adductor thigh muscle due to cervical cord injury had obturator nerve neurolysis done with botulinum toxin type B (BoNT-B). Most of the previous studies have used BoNT-A with only a few reports that have used BoNT-B. BoNT-B has several advantages and disadvantages over BoNT-A. Thus, we report herein a patient who successfully received obturator nerve neurolysis using BoNT-B to treat adductor thigh muscle spasm.